Latham & Watkins Represents Vera Therapeutics in US$300 Million Offering of Common Stock

Vera Therapeutics, Inc., a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, announced an underwritten public offering of 7,058,824 shares of its Class A common stock at a price to the public of US$42.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 920,716 additional shares of its Class A common stock. The gross proceeds to Vera Therapeutics from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are approximately US$300 million. The offering closed on December 11, 2025.

Latham & Watkins LLP represented Vera Therapeutics in the offering with a Capital Markets team led by partners Keith Halverstam and Elisabeth Martin, with associates Amanda Farrish and Jessica Kerr, and assistance from Chanie Saltzman. Advice was also provided on FDA matters by partner Elizabeth Richards and counsel Chad Jennings, with associate Evan Miller; on healthcare matters by partner Betty Pang; on tax matters by partner Katharine Moir, with associate Dennis Poehland; and on public company representation matters by counsel Emily Corbi.